Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity

Multiple Sclerosis

Volumn 22, Issue 12, 2016, Pages 1550-1559

  Kuhle, Jens ^a   Barro, Christian ^a   Disanto, Giulio ^b   Mathias, Amandine ^c   Soneson, Charlotte ^d,e   Bonnier, Guillaume ^e   Yaldizli, Özguer ^a   Regeniter, Axel ^f   Derfuss, Tobias ^a   Canales, Mathieu ^c   Schluep, Myriam ^c   Du Pasquier, Renaud ^g   Krueger, Gunnar ^a   Granziera, Cristina ^e  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Ospedale Civico Lugano   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f Advanced Clinical Imaging Technology   (Switzerland)

^g EPFL   (Switzerland)

Author keywords

magnetization transfer ratio (MTR); Neurofilament light chain (NfL); relaxometry; serum; white matter lesions

Indexed keywords

BIOLOGICAL MARKER; NEUROFILAMENT LIGHT CHAIN; NEUROFILAMENT PROTEIN; UNCLASSIFIED DRUG; NEUROFILAMENT PROTEIN L;

ADULT; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROIMMUNOASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; LIMIT OF QUANTITATION; LONGITUDINAL STUDY; MAGNETIZATION TRANSFER RATIO; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; RADIODIAGNOSIS; RELAPSE; RELAXATION TIME; REMISSION; WHITE MATTER LESION; BLOOD; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; PATHOLOGY; SEVERITY OF ILLNESS INDEX; WHITE MATTER; YOUNG ADULT;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROFILAMENT PROTEINS; SEVERITY OF ILLNESS INDEX; WHITE MATTER; YOUNG ADULT;

EID: 84991320278     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515623365     Document Type: Article

References (36)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
2. Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE 2013; 8: e75091.
3. Kuhle J, Gaiottino J, Leppert D, et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry 2014; 86 (3): 273-279.
4. Disanto G, Adiutori R, Dobson R, et al. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry. Epub ahead of print 25 2015. DOI: 10.1136/jnnp-2014-309690.
5. Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. Epub ahead of print 1 2015. DOI: 10.1212/WNL.0000000000001642.
6. Bonnier G, Roche A, Romascano D, et al. Advanced MRI unravels the nature of tissue alterations in early multiple sclerosis. Ann Clin Transl Neurol 2014; 1: 423-432.
7. Romascano D, Meskaldji DE, Bonnier G, et al. Multicontrast connectometry: A new tool to assess cerebellum alterations in early relapsing-remitting multiple sclerosis. Hum Brain Mapp 2015; 36: 1609-1619.
8. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
9. Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006; 23: 312-328.
10. Schmitter D, Roche A, Marechal B, et al. An evaluation of volume-based morphometry for prediction of mild cognitive impairment and Alzheimer's disease. Neuroimage Clin 2015; 7: 7-17.
11. Granziera C, Daducci A, Simioni S, et al. Micro-structural brain alterations in aviremic HIV+ patients with minor neurocognitive disorders: A multi-contrast study at high field. PLoS ONE 2013; 8: e72547.
12. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc 1995; 57: 289-300.
13. Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014; 75: 116-126.
14. Herbert MK, Aerts MB, Beenes M, et al. CSF neurofilament light chain but not FLT3 ligand discriminates parkinsonian disorders. Front Neurol 2015; 6: 91.
15. Kuhle J, Plattner K, Bestwick JP, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler 2013; 19: 1597-1603.
16. Romme CJ, Bornsen L, Khademi M, et al. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler 2013; 19: 877-884.
17. Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009; 72: 1322-1329.
18. Petzold A,. The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up. J Neurol Neurosurg Psychiatry. Epub ahead of print 23 2015. DOI: 10.1136/jnnp-2014-309827.
19. Salzer J, Svenningsson A, Sundstrom P,. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010; 16: 287-292.
20. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83-89.
21. Kuhle J, Disanto G, Lorscheider J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015; 84: 1639-1643.
22. Romme CJ, Ratzer R, Bornsen L, et al. Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial. Neurology 2014; 82: 1499-1507.
23. Reiber H,. Proteins in cerebrospinal fluid and blood: Barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci 2003; 21: 79-96.
24. Modvig S, Degn M, Horwitz H, et al. Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS ONE 2013; 8: e77163.
25. Burman J, Zetterberg H, Fransson M, et al. Assessing tissue damage in multiple sclerosis: A biomarker approach. Acta Neurol Scand 2014; 130: 81-89.
26. Khalil M, Enzinger C, Langkammer C, et al. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler 2013; 19: 436-442.
27. Malmestrom C, Haghighi S, Rosengren L, et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003; 61: 1720-1725.
28. Villar LM, Picon C, Costa-Frossard L, et al. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. Eur J Neurol. Epub ahead of print 17. DOI: 10.1111/ene.12579.
29. Lycke JN, Karlsson JE, Andersen O, et al. Neurofilament protein in cerebrospinal fluid: A potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 402-404.
30. Schlaepfer WW, Lynch RG,. Immunofluorescence studies of neurofilaments in the rat and human peripheral and central nervous system. J Cell Biol 1977; 74: 241-250.
31. Zetterberg H, Hietala MA, Jonsson M, et al. Neurochemical aftermath of amateur boxing. Arch Neurol 2006; 63: 1277-1280.
32. Petzold A,. Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005 15; 233: 183-198.
33. Helms G,. Tissue properties from quantitative MRI. Brain mapping: An encyclopedic reference (ed. Toga AW,) New York: Elsevier, 2015.
34. Stuber C, Morawski M, Schafer A, et al. Myelin and iron concentration in the human brain: A quantitative study of MRI contrast. Neuroimage 2014; 1: 95-106.
35. Barkovich AJ,. Concepts of myelin and myelination in neuroradiology. AJNR Am J Neuroradiol 2000; 21: 1099-1109.
36. Petzold A, Tozer DJ, Schmierer K,. Axonal damage in the making: Neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter. Exp Neurol 2011; 232: 234-239.